Form D · Pharmaceuticals
Octagon Therapeutics, Inc.
Providence, RI · CIK 0001756982
Offering snapshot reported Feb 12, 2024 · SEC filing
- Reported sold
- $11M Offering amount: $12.4M
- Investors reported
- 53 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 29, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 12, 2024 | Initial | $10,970,135 | No comparison | 53 | SEC filing |
| Jun 10, 2020 | Initial | $398,000 | No comparison | 8 | SEC filing |
| Nov 26, 2019 | Initial | $511,000 | No comparison | 10 | SEC filing |
| Oct 25, 2018 | Initial | $537,588 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-504975
Source: Form D, filed Feb 12, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Fred Ausubel | Director, Executive |
| Paul Goldenheim | Director |
| Ronald Lennox | Director |
| Thorne Sparkman | Director |
| Isaac Stoner | Director, Executive |
| Shen Yu | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
225 Dyer St.
Providence, RI, 02903
Providence, RI, 02903